PureTech Founded Entity Seaport Therapeutics Announces Positive Proof of Concept Results

The Phase 1 trial of GlyphAgo in healthy volunteers showed promising topline data.

Apr. 2, 2026 at 3:26pm

Got story updates? Submit your updates here. ›

A translucent, ghostly X-ray image of a complex molecular structure or biological compound, its intricate lines and shapes glowing with a soft blue-green light against a dark background, conveying the scientific and medical nature of the story.Promising early-stage trial results for PureTech's drug candidate GlyphAgo offer hope for new therapeutic approaches.Boston Today

PureTech Health, a biotherapeutics company, announced that its founded entity Seaport Therapeutics has reported positive topline results from portions of an ongoing Phase 1 trial of its drug candidate GlyphAgo in healthy volunteers. These initial data strengthen the company's confidence in GlyphAgo's potential and provide further clinical validation for the Glyph platform.

Why it matters

The positive proof-of-concept data for GlyphAgo, an early-stage drug candidate, is an important milestone for PureTech and its Seaport Therapeutics subsidiary. Successful early-stage trials can pave the way for further development and potential commercialization of new therapies, which could benefit patients.

The details

The Phase 1 trial of GlyphAgo is evaluating the safety, tolerability, and pharmacokinetics of the drug candidate in healthy volunteers. Seaport Therapeutics reported that the topline data from portions of this ongoing trial showed promising results, strengthening the company's conviction in GlyphAgo's potential.

  • The Phase 1 trial of GlyphAgo is currently ongoing.

The players

PureTech Health plc

A hub-and-spoke biotherapeutics company dedicated to giving life to science and transforming innovation into value.

Seaport Therapeutics

A founded entity of PureTech Health that is developing the GlyphAgo drug candidate.

GlyphAgo

A drug candidate being developed by Seaport Therapeutics, a PureTech founded entity.

Got photos? Submit your photos here. ›

The takeaway

The positive proof-of-concept results for GlyphAgo in this early-stage trial represent an important milestone for PureTech and its Seaport Therapeutics subsidiary, as they work to develop new therapies that could potentially benefit patients.